Evidence map›Paper›PMID 30123403›Full record

ArticleRevista Puertorriquena de medicina y salud publica2018

[Survival analysis in people diagnosed with HIV/AIDS in Puerto Rico].

Melissa Marzán-Rodríguez, Diego E Zavala Segarra, Juan Carlas Orengo Valverde, Nelson Varas-Díaz, Sandra Miranda De León, Eliseo Acevedo-Díaz

Abstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Revista Puertorriquena de medicina y salud publica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Melissa Marzán-RodríguezEs Investigadora Post-Doctoral en el Centro de Investigación y Evaluación Sociomédica del Recinto de Ciencias Médicas de la Universidad de Puerto Rico. Profesora Asistente en Epidemiología del Programa de Salud Pública de la Ponce Health Sciences University
Diego E Zavala SegarraEs Director del Registro de Cáncer de Puerto Rico, Co-InvestigadorPrincipal del Sistema de Muertes Violentas de Puerto adscrito al Instituto de Estadística de Puerto Rico y Profesoren Epidemiología del Programa de Salud Pública de la Ponce Health Sciences University.
Juan Carlas Orengo ValverdeEs Profesor e Investigador en Epidemiología del Programa de Salud Pública de la Ponce Health Sciences University. También funge como Co-Líder en el Puerto Rico Clinical Traslational Research Consortium (PRCTRC).
Nelson Varas-DíazProfesor e Investigador en el Departamento de Estudios Socioculturales y Globales en la Escuela de Asuntos Internacionales y Públicos de la Florida International University.
Sandra Miranda De LeónEpidemióloga y Directora del Sistema de Vigilancia de VIH de la Oficina de Epidemiologia e Investigación del Departamento de Salud de Puerto Rico.
Eliseo Acevedo-DíazBioestadístico en el Departamento de Epidemiología de la Johns Hopkins University.

Funding

Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
HIV/AIDS Stigma Behaviors in Clinical EncountersK02DA035122 · NIDA · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI VARAS-DIAZ, NELSON · 2014 to 2018
$578k
NIDA NIH HHS K02 DA035122NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

After the introduction of HAART, the HIV/AIDS epidemiological trends has shown an increasing in the survival rates. HAART has dramatically improved the life expectancy of HIV/AIDS. The objective of this study was to estimate survival in people diagnosed with HIV/AIDS in Puerto Rico (PR) from 2003-2011. A population-based study using the PR HIV Surveillance System was implemented. A total of N = 9,290 people were diagnosed with HIV/AIDS in PR for 2003-2011 period. Cox regression models for survival analysis were assessed. Survival at 6 years after diagnosis in HIV patients was 0.87 (CI95%: 0.09, 0.72) when compare with AIDS patients at same time of diagnosis was 0.57 (CI95%: 0.55, 0.60) p<0.001. Intravenous drug users [IDU] have less probability of survival at 5 years after diagnosis when compare with other transmission modes 0.69 (CI95%: 0.67, 0.71) p<0.001. Assertive prevention strategies must be developed and implemented in PR for IDU's in order to increase their survival rates.

Indexed as

HIV/AIDSmodes of transmissionPuerto RicosexSurvival analysis

Identifiers

PMID30123403
PMCPMC6097805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.